Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab
This study introduces a biomarker-focused model for estimating ICERs across diverse diseases, enabling informed decision-making in healthcare resource allocation. Further research is recommended to broaden the model's applicability and address additional population heterogeneity factors.
Authors
- Farhad Shahi
- Shekoufeh Nikfar (ORCID: https://orcid.org/0000-0002-5206-6197)
- Marzieh Nosrati (ORCID: https://orcid.org/0000-0001-8964-1653)
- Mandana Hasanzad (ORCID: https://orcid.org/0000-0002-0538-1135)
- Mohammad Abdollahı (ORCID: https://orcid.org/0000-0003-0123-1209)
- Akbar Abdollahi Asl
- Mohammad Hossein Sharifnia
- Hossein Vatankhah
- Mahdi Asfia
Institutions
- Islamic Azad University, Tehran (IR)
- University of Tehran (IR)
- Tehran University of Medical Sciences (IR)
- University of California, Davis (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1080/14737167.2025.2526065
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Tehran University of Medical Sciences and Health Services